Physician profile
Scott E Sanders
NPI 1780670927
$33,377.40
in general payments reported to CMS, 2019-2025
43 companies · $7,180 in 2025
The $7,180 reported for 2025 was more than what 94% of Dermatopathology (Dermatology) providers received nationally (typical 2025 total: $251).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,805 · 2020: $1,644 · 2021: $2,851 · 2022: $5,745 · 2023: $6,544 · 2024: $6,606 · 2025: $7,180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $20K · Education: $594.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $19,736.42 |
| Education | $594.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,377.35 | 2019-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $4,603.31 | 2019-2025 | Tremfya, Simponi, Stelara |
| Regeneron Healthcare Solutions, INC. | $2,192.25 | 2019-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $2,048.26 | 2019-2025 | |
| Genzyme Corporation | $2,026.75 | 2019-2025 | |
| Pfizer INC. | $1,993.38 | 2019-2025 | |
| Incyte Corporation | $1,744.62 | 2021-2025 | Opzelura, Opzelura |
| Ucb, INC. | $1,552.38 | 2019-2025 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $1,551.28 | 2019-2025 | Ilumya, Blu-U, Odomzo |
| Dermavant Sciences, INC. | $1,430.99 | 2022-2024 | Vtama |
| Amgen INC. | $1,002.45 | 2021-2025 | Otezla, Otezla |
| Lilly USA, LLC | $951.21 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $877.26 | 2022-2025 | Sotyktu |
| Leo Pharma INC. | $807.17 | 2019-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $688.48 | 2019-2025 | Nemluvio, Aklief, Dysport |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $641.80 | 2019-2024 | Siliq, Targretin, Duobrii |
| Arcutis Biotherapeutics, INC. | $539.62 | 2023-2025 | Zoryve |
| Genentech USA, INC. | $474.33 | 2019-2022 | |
| Helsinn Therapeutics (U.S.), INC. | $394.55 | 2019-2025 | Valchlor |
| Botanix Sb INC | $253.76 | 2025 | Sofdra |
| Organon LLC | $238.00 | 2023-2025 | Vtama, Hadlima, Nexplanon |
| Blueprint Medicines Corporation | $209.10 | 2024 | Ayvakit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $206.89 | 2022-2024 | Cyltezo, Spevigo |
| Biofrontera INC. | $168.70 | 2019-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Almirall LLC | $146.05 | 2019-2022 | |
| Paratek Pharmaceuticals, INC. | $145.46 | 2023-2025 | Nuzyra |
| Journey Medical Corporation | $141.85 | 2020-2023 | |
| Vyne Pharmaceuticals INC. | $139.31 | 2020-2021 | |
| Celgene Corporation | $124.23 | 2019 | |
| Lnhc, INC | $106.57 | 2025 | Zelsuvmi |
| Epi Health, LLC | $98.13 | 2020-2022 | |
| Alnylam Pharmaceuticals INC. | $88.58 | 2023-2025 | Givlaari |
| Kyowa Kirin, INC. | $87.38 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $67.78 | 2023 | Purified Cortrophin Gel |
| Aclaris Therapeutics, INC. | $58.90 | 2019 | |
| Sensus Healthcare, INC. | $36.47 | 2019 | |
| Sandoz INC. | $34.23 | 2020 | |
| Prugen, INC. Pharmaceuticals | $29.43 | 2019 | |
| Dusa Pharmaceuticals, INC. | $24.27 | 2019 | |
| Mallinckrodt Hospital Products INC. | $20.37 | 2024 | Acthar |
| Sanofi-Aventis U.S. LLC | $20.35 | 2019 | |
| Promius Pharma LLC | $19.46 | 2019 | |
| Dermira, INC. | $14.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Sanders listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.